antisens
oligonucleotid
short
singlestrand
dna
molecul
design
inhibit
translat
target
gene
protein
via
interact
messeng
rna
rna
interfer
rnai
relat
technolog
incorpor
antisens
featur
employ
small
interf
si
rna
molecul
rather
dna
lung
attract
target
antisens
oligonucleotid
sirna
technolog
drug
deliveri
organ
without
system
exposur
feasibl
antisens
oligonucleotid
direct
signal
molecul
cytokin
receptor
transcript
factor
involv
allerg
respons
appli
experiment
model
asthma
demonstr
potenti
therapeut
equal
excit
sever
antisensebas
drug
direct
oncogen
develop
therapi
lung
cancer
current
latestag
clinic
trial
notabl
oblimersen
antisens
oligonucleotid
target
antiapoptot
protein
phase
iiiii
trial
genta
although
develop
antisens
oligonucleotid
sirna
therapi
lung
infect
still
earli
stage
develop
initi
studi
yield
promis
result
medic
import
pathogen
respiratori
syncyti
viru
issu
specif
identif
correct
molecular
target
drugdeliveri
carrier
system
potenti
advers
effect
must
care
evalu
clinic
applic
antisensebas
therapi
promis
new
technolog
lung
diseas
may
becom
commerci
realiti
near
futur
prevent
product
diseaserel
protein
reduc
elimin
messeng
rna
attract
concept
clinic
therapi
differ
significantli
use
tradit
drug
design
inhibit
diseaserel
protein
alreadi
present
two
major
therapeut
method
alter
mrna
level
antisens
rna
interfer
rnai
antisens
current
develop
technolog
antisens
oligonucleotid
aso
short
singlestrand
dna
molecul
design
block
translat
target
gene
protein
interact
mrna
although
concept
use
antisens
specif
inhibit
gene
express
first
propos
almost
year
ago
year
pass
commerci
first
current
antisens
drug
clinic
use
fomivirsen
isi
pharmaceut
aso
use
topic
treat
cytomegalovirusassoci
retin
patient
aid
rnai
relat
technolog
incorpor
antisens
featur
employ
small
interf
rna
sirna
molecul
rather
dna
yet
commerci
clinic
therapi
despit
limit
success
date
theoret
advantag
mrnatarget
technolog
convent
drug
see
drug
candid
current
undergo
clinic
trial
hundr
preclin
develop
earli
research
lung
attract
target
aso
rnai
technolog
drug
deliveri
organ
achiev
rel
easili
limit
system
involv
howev
ongo
develop
mrnatarget
drug
must
address
sever
import
practic
issu
relat
clinic
applic
overcom
problem
oligonucleotid
degrad
sever
chemic
modif
aso
develop
first
still
commonli
use
phosphorothio
backbon
compris
replac
nonbridg
oxygen
atom
sulfur
atom
phosphoru
group
presenc
sulfur
atom
substanti
hinder
degrad
nucleas
follow
system
administr
phosphorothio
oligonucleotid
bind
plasma
protein
ensur
prolong
effect
sever
structur
modif
also
develop
includ
methyloligonucleotid
morpholino
peptid
nucleic
acid
lock
nucleic
acid
although
improv
stabil
nucleas
increas
bind
affin
mrna
also
drawback
low
cell
penetr
lack
rnase
h
recruit
critic
issu
develop
antisensebas
therapi
respiratori
diseas
includ
biolog
stabil
deliveri
target
organ
cell
target
select
specif
rnai
also
incorpor
antisens
featur
employ
sirna
molecul
rather
dna
rnai
involv
intracellular
cleavag
foreign
doublestrand
ds
rna
sirna
molecul
follow
degrad
endogen
mrna
complementari
antisens
strand
sirna
discov
rnai
natur
occur
process
part
innat
antivir
defens
lower
eukaryot
much
enthusiasm
potenti
power
therapeut
tool
specif
inhibit
gene
express
although
transfect
mammalian
cell
dsrna
induc
strong
interferonlik
respons
eventu
lead
program
cell
death
apoptosi
treatment
sirna
initi
rnai
without
caus
cell
death
use
sirna
promis
therapi
genet
diseas
sinc
sirna
target
singl
nucleotid
polymorph
thu
specif
target
select
oncogen
howev
clinic
applic
sirna
still
problemat
mechan
rnai
higher
eukaryot
fulli
understood
potenti
offtarget
advers
effect
addit
deliveri
cellular
uptak
sirna
less
effici
aso
doublestrand
sirna
bind
plasma
protein
rapidli
degrad
tissu
environ
correct
target
select
critic
develop
asobas
therapi
respiratori
diseas
target
molecul
must
import
diseas
pathogenesi
aso
extrem
potent
must
also
specif
lung
diseas
avoid
potenti
advers
effect
clinic
relev
target
protein
select
specif
aso
critic
issu
must
inhibit
express
target
gene
gene
similar
sequenc
ie
target
mrna
sequenc
homolog
gene
therefor
design
aso
genom
care
check
possibl
hybrid
aso
sequenc
nontarget
gene
sequenc
common
sever
molecul
famili
domain
express
mani
gene
must
avoid
cation
liposom
complex
aso
often
use
intraven
local
deliveri
aso
airway
complex
intern
cell
effici
nake
aso
upon
system
applic
cancer
therapi
asoliposom
complex
preferenti
enter
tumor
tissu
increas
permeabl
blood
vessel
tumor
addit
cation
lipid
greatli
enhanc
immunostimulatori
properti
dna
provid
addit
therapeut
effect
may
import
cancer
therapi
howev
immunostimul
also
advers
effect
although
carrier
polyethylenimin
pei
chitosandna
nanospher
develop
altern
cation
liposom
carrierrel
advers
effect
seen
use
natur
surfact
cation
properti
becom
attract
new
method
aso
deliveri
lung
advers
effect
aso
therapi
result
nonspecif
hybrid
aso
nonspecif
activ
rnase
h
offtarget
biolog
effect
oligonucleotid
deliveri
system
nonspecif
hybrid
aso
nonspecif
activ
rnase
h
result
reduc
express
nontarget
gene
consequ
advers
effect
phosphorothioatemodifi
oligonucleotid
bind
famili
heparinbind
protein
includ
certain
growth
factor
receptor
extracellular
matrix
protein
adhes
molecul
least
partial
explain
advers
effect
low
platelet
count
low
blood
pressur
presenc
immunostimulatori
cytosineguanin
dinucleotid
cpg
motif
within
aso
normal
undesir
stimul
tolllik
receptor
tlr
sever
cell
type
import
sourc
advers
effect
relat
system
cytokin
releas
fatigu
fever
flulik
syndrom
howev
instanc
may
includ
addit
benefici
effect
immun
system
induct
proinflammatori
cytokin
also
caus
sirna
molecul
bind
tlr
present
immun
cell
elicit
cellular
activ
local
deliveri
aso
offer
advantag
system
administr
allow
lower
dose
use
thu
minim
system
toxic
import
consider
use
aso
airway
adenosin
releas
oligonucleotid
degrad
product
activ
adenosin
receptor
induc
bronchoconstrict
inde
adenosin
receptor
upregul
certain
clinic
condit
notabl
asthma
target
aso
treatment
asthma
sourc
potenti
advers
effect
deliveri
system
cation
liposom
complex
may
enhanc
immunostimulatori
effect
aso
trigger
releas
proinflammatori
cytokin
may
directli
affect
cellular
function
tyrosin
kinas
syk
mediat
earli
signal
event
import
pathophysiolog
allerg
asthma
initi
crosslink
high
affin
receptor
ige
mast
cell
basophil
treatment
rat
nebul
syk
asoliposom
complex
shown
inhibit
syk
mrna
protein
express
alveolar
macrophag
addit
aerosol
syk
aso
inhibit
mani
central
compon
allerg
asthma
inflamm
anim
model
diseas
inflammatori
cell
infiltr
airway
lung
eosinophilia
increas
eosinophil
leukocyt
increas
tumor
necrosi
factor
bronchoalveolar
lavag
induc
antigen
challeng
syk
aso
also
suppress
antigeninduc
tracheal
contract
howev
although
syk
promis
molecular
target
aso
therapi
asthma
inflammatori
condit
acut
lung
injuri
potenti
risk
relat
syk
inhibit
exampl
recent
studi
implic
syk
tumor
suppressor
gene
breast
gastric
cancer
thu
syk
aso
may
advantag
shortterm
local
therapi
sever
lung
condit
exampl
acut
respiratori
distress
syndrom
longterm
applic
syk
aso
rais
potenti
safeti
issu
must
assess
lyn
srcfamili
kinas
anoth
potenti
target
aso
therapi
asthma
lyn
signal
activ
syk
implic
pathogenesi
asthma
although
aso
therapi
target
lyn
yet
appli
experiment
model
asthma
asthma
complex
heterogen
diseas
involv
multipl
gene
poorli
understood
geneenviron
interact
major
challeng
antisensebas
therapi
identifi
appropri
molecular
target
use
aso
target
point
intracellular
pathway
involv
inflammatori
cell
activ
also
investig
exampl
inhal
aso
target
mitogenactiv
protein
kinas
reduc
asthma
symptom
murin
model
similarli
intraven
administr
aso
target
subunit
rela
proinflammatori
transcript
factor
nuclear
factor
kappa
b
significantli
inhibit
allerg
respons
mous
model
nevertheless
despit
proofofprincipl
studi
system
administr
aso
would
appear
feasibl
therapeut
strategi
asthma
given
crucial
involv
transcript
factor
regul
immun
respons
given
import
role
helper
type
cytokin
receptor
allerg
asthma
variou
molecul
involv
signal
pathway
investig
target
aso
therapi
includ
interleukin
il
stem
cell
factor
kit
ligand
transcript
factor
signal
transduc
activ
transcript
stat
rodent
model
asthma
aso
target
mediat
found
allevi
diseas
symptom
intratrach
inject
aso
target
common
chain
granulocytemacrophag
colonystimul
factor
gmcsf
receptor
significantli
reduc
diseas
symptom
rat
model
asthma
approach
move
forward
clinic
test
directli
target
bronchial
smooth
muscl
contract
asthma
aso
type
adenosin
receptor
administ
aerosol
form
rabbit
found
significantli
reduc
bronchoconstrict
airway
inflamm
asobas
therapi
current
phase
ii
clinic
trial
previous
describ
aso
approach
asthma
therapi
administ
phosphorothio
oligonucleotid
either
liposom
deliveri
system
nake
dna
recent
adenovirusmedi
intracellular
express
aso
employ
deliveri
method
success
anim
model
asthma
use
recombin
adenoviru
aso
deliveri
target
cell
offer
advantag
method
select
airway
epithelium
prolong
express
transfect
asoencod
gene
week
follow
instil
howev
adenovirusmedi
gene
deliveri
induc
immun
respons
adenoviru
preclud
repeat
applic
sever
safeti
concern
potenti
oncogen
transform
recent
approach
includ
use
ribozym
rna
enzym
sirna
use
ribozym
offer
advantag
tradit
antisens
catalyt
rna
molecul
recycl
induc
cleavag
complementari
mrna
cleavag
therefor
appear
act
effici
dnabas
antisens
recent
studi
employ
sirna
silenc
gene
express
transcript
regul
cytokin
subsequ
reduct
certain
inflammatori
respons
human
bronchial
epitheli
cell
antisens
technolog
decept
simpl
concept
practic
proven
difficult
implement
howev
sign
technolog
final
emerg
valid
therapeut
platform
import
note
anim
studi
asthma
aso
variou
target
molecul
appli
prior
antigen
challeng
whether
aso
therapi
also
effect
ongo
allerg
inflamm
requir
studi
new
target
antisens
therapi
asthma
also
emerg
genet
studi
identifi
sever
potenti
asthma
suscept
gene
inflammatori
mediat
disintegrin
metalloproteas
domain
gprotein
coupl
receptor
asthma
suscept
gpra
although
biochem
mechan
link
mani
candid
gene
asthma
pathogenesi
poorli
understood
aso
strategi
may
help
elucid
pathway
lung
cancer
mani
oncogen
identifi
target
antisens
therapi
sever
antisensebas
drug
reach
phase
clinic
trial
may
soon
approv
clinic
use
particular
promis
aso
direct
gene
encod
antiapoptot
protein
oblimersen
induc
apoptosi
nonsmallcel
lung
cancer
cell
potenti
effect
chemotherapi
genasens
current
undergo
phase
iiiii
clinic
trial
genta
therapi
smallcel
nonsmallcel
lung
cancer
combin
chemotherapi
target
antisens
therapi
lung
cancer
evalu
clinic
trial
often
combin
chemotherapi
includ
signal
transduct
molecul
protein
kinas
regulatori
subunit
protein
kinas
raf
kinas
protein
encod
hra
oncogen
gener
aso
drug
studi
clinic
trial
lung
cancer
short
mer
phosphorothio
oligonucleotid
infus
intraven
associ
moder
dosedepend
system
toxic
decreas
platelet
thrombocytopenia
flulik
syndrom
low
blood
pressur
weak
unfortun
publish
report
local
applic
aso
lung
cancer
numer
preclin
studi
focus
molecular
target
involv
regul
apoptosi
cell
cycl
progress
angiogenesi
metastasi
includ
apoptosi
suppressor
survivin
cytochrom
c
oxidas
assembl
protein
sever
growth
factor
receptor
receptor
tyrosin
kinas
well
transcript
factor
although
human
cancer
cell
line
preserv
rnai
machineri
therefor
use
sirna
silenc
oncogen
involv
cancer
pathogenesi
suggest
sirnabas
strategi
lung
cancer
therapi
remain
earli
stage
investig
develop
antisensebas
drug
therapi
lung
infect
earlier
stage
develop
antisens
program
asthma
lung
cancer
preliminari
studi
success
antisens
strategi
target
respiratori
syncyti
viru
rsv
combin
antivir
drug
ribavirin
addit
sirna
strategi
target
rsv
parainfluenza
viru
recent
discov
coronaviru
sarscov
caus
agent
sever
acut
respiratori
syndrom
sar
shown
promis
result
anim
studi
effort
signal
begin
potenti
import
research
area
opportun
develop
innov
aso
therapi
infecti
diseas
lung
antisens
technolog
decept
simpl
concept
practic
proven
difficult
implement
pharmacotherapi
howev
sign
technolog
final
emerg
valid
therapeut
platform
variou
asobas
drug
candid
show
promis
treatment
respiratori
diseas
asthma
lung
cancer
viral
infect
appli
aso
complex
heterogen
diseas
asthma
present
major
challeng
sinc
condit
involv
sever
pathway
numer
gene
poorli
understood
geneenviron
interact
despit
approach
specif
target
critic
molecul
asthma
success
develop
asobas
drug
clinic
applic
anticip
near
futur
effort
aid
greatli
rapidli
develop
field
asthma
genet
aso
therapi
also
potenti
becom
power
tool
lung
cancer
success
anticip
base
intens
molecular
studi
discoveri
causal
oncogen
lung
cancer
aso
drug
candid
latestag
clinic
trial
although
applic
rnai
uniqu
challeng
sever
compani
program
develop
sirnabas
therapi
respiratori
diseas
tabl
ongo
critic
challeng
develop
asobas
therapeut
includ
select
correct
target
protein
minim
sequencespecif
eg
cpgmediat
sequencenonspecif
eg
phosphorothioatemedi
advers
effect
new
methodolog
deliveri
aso
select
target
cell
optim
carrier
system
like
provid
import
advanc
therapeut
use
aso
